Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation
Stack the two gaps together and the picture for the conventional protocol is unflattering: approximately one-fifteenth of the studied dose, delivered by a route that animal data suggest requires several-fold more peptide, targeting a compound whose dose-response may not be monotonic anyway
This process showed good moldability, even distribution, and controllable release over time, which made it a good choice for protecting the rectal area from radiation
Shenuarin Bhuiyan 2 Gretchen Galliano 8 Bo Wei 9 Lin Tan 9 Iqbal Mahmud 9 Ida Surakka 3 Minerva Garcia-Barrio 3 Philip Lorenzi 9 Eyal Gottlieb 9 Eduardo Salido 10 Jifeng Zhang 3 Wayne Orr 2 Wanqing Liu 11 Monica Diaz-Gavilan 12 Eugene Chen 3 Nirav Dhanesha 2 Paul Thevenot 8 Ari Cohen 8 Arif Yurdagul 2 , 1 LSU Health Shreveport, 2 LSU Health, Shreveport, LA, USA, 3 University of Michigan, Ann Arbor, MI, USA, 4 Ochsner Health, New Orleans, LA, USA, 5 University of Michigan School of Public Health, Ann Arbor, MI 48109, USA, 6 Unidad de Excelencia de Qumica Aplicada a Biomedicina y Medioambiente, Campus Cartuja s/n, Spain, 7 University of Pittsburgh, Pittsburgh, PA, 15261, USA, 8 Ochsner Medical Center - New Orleans, LA, USA, 9 MD Anderson Cancer Center, Houston, TX 77030, 10 Universidad de La Laguna, Tenerife 38320, Spain, 11 Wayne State University, MI, USA, 12 Unidad de Excelencia de Qumica Aplicada a Biomedicina y Medioambiente, Granada, Spain Background: Metabolic dysfunction-associated steatohepatitis (MASH) is on the rise, and with limited pharmacological therapy available, identification of new metabolic targets is urgently needed
